Table of Contents Author Guidelines Submit a Manuscript
PPAR Research
Volume 2006 (2006), Article ID 93258, 8 pages
http://dx.doi.org/10.1155/PPAR/2006/93258
Research Article

The Genetics of PPARG and the Skeleton

1The Jackson Laboratory, Bar Harbor ME 04609, USA
2St. Joseph's Hospital, The Maine Center for Osteoporosis Research and Education, Bangor ME 04401, USA

Received 31 March 2006; Revised 27 June 2006; Accepted 5 July 2006

Copyright © 2006 Cheryl Ackert-Bicknell and Clifford Rosen. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. 1994 WHO assessment of fracture risk and its application to screening for postmenopausal osteoporosis. WHO technical reports series 834.
  2. S CE Schuit, M van der Klift, A EAM Weel et al., “Fracture incidence and association with bone mineral density in elderly men and women: the Rotterdam Study,” Bone, vol. 34, no. 1, pp. 195–202, 2004. View at Publisher · View at Google Scholar
  3. Q-Y Huang, R R Recker, and H-W Deng, “Searching for osteoporosis genes in the post-genome era: progress and challenges,” Osteoporosis International, vol. 14, no. 9, pp. 701–715, 2003. View at Publisher · View at Google Scholar
  4. J Zmuda, Y Sheu, and S Moffett, “The search for human osteoposis genes,” Journal of Musculoskeletal & Neuronal Interactions, vol. 6, no. 1, pp. 3–15, 2006. View at Google Scholar
  5. A Schwartz, “Diabetes mellitus: does it affect bone?” Calcified Tissue International, vol. 73, no. 6, pp. 515–519, 2003. View at Publisher · View at Google Scholar
  6. P A Marcovitz, H H Tran, B A Franklin et al., “Usefulness of bone mineral density to predict significant coronary artery disease,” The American Journal of Cardiology, vol. 96, no. 8, pp. 1059–1063, 2005. View at Publisher · View at Google Scholar
  7. H S Glauber, W M Vollmer, M C Nevitt, K E Ensrud, and E S Orwoll, “Body weight versus body fat distribution, adiposity, and frame size as predictors of bone density,” Journal of Clinical Endocrinology & Metabolism, vol. 80, no. 4, pp. 1118–1123, 1995. View at Publisher · View at Google Scholar
  8. P Meunier, J Aaron, C Edouard, and G Vignon, “Osteoporosis and the replacement of cell populations of the marrow by adipose tissue. A quantitative study of 84 iliac bone biopsies,” Clinical Orthopaedics and Related Research, vol. 80, pp. 147–154, 1971. View at Publisher · View at Google Scholar
  9. J Justesen, K Stenderup, E N Ebbesen, L Mosekilde, T Steiniche, and M Kassem, “Adipocyte tissue volume in bone marrow is increased with aging and in patients with osteoporosis,” Biogerontology, vol. 2, no. 3, pp. 165–171, 2001. View at Publisher · View at Google Scholar
  10. S Verma, J H Rajaratnam, J Denton, J A Hoyland, and R J Byers, “Adipocytic proportion of bone marrow is inversely related to bone formation in osteoporosis,” Journal of Clinical Pathology, vol. 55, no. 9, pp. 693–698, 2002. View at Publisher · View at Google Scholar
  11. S C Manolagas, “Birth and death of bone cells: basic regulatory mechanisms and implications for the pathogenesis and treatment of osteoporosis,” Endocrine Reviews, vol. 21, no. 2, pp. 115–137, 2000. View at Publisher · View at Google Scholar
  12. P Ducy, R Zhang, V Geoffroy, A L Ridall, and G Karsenty, “Osf2/Cbfa1: a transcriptional activator of osteoblast differentiation,” Cell, vol. 89, no. 5, pp. 747–754, 1997. View at Publisher · View at Google Scholar
  13. P Tontonoz, E Hu, and B M Spiegelman, “Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor,” Cell, vol. 79, no. 7, pp. 1147–1156, 1994. View at Publisher · View at Google Scholar
  14. B Lecka-Czernik, I Gubrij, E J Moerman et al., “Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPAR?2,” Journal of Cellular Biochemistry, vol. 74, no. 3, pp. 357–371, 1999. View at Publisher · View at Google Scholar
  15. J M Gimble, C E Robinson, X Wu et al., “Peroxisome proliferator-activated receptor-? activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells,” Molecular Pharmacology, vol. 50, no. 5, pp. 1087–1094, 1996. View at Google Scholar
  16. E J Moerman, K Teng, D A Lipschitz, and B Lecka-Czernik, “Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: the role of PPAR-γ2 transcription factor and TGF-β/BMP signaling pathways,” Aging Cell, vol. 3, no. 6, pp. 379–389, 2004. View at Publisher · View at Google Scholar
  17. B M Spiegelman, “PPAR-γ: adipogenic regulator and thiazolidinedione receptor,” Diabetes, vol. 47, no. 4, pp. 507–514, 1998. View at Publisher · View at Google Scholar
  18. L Fajas, D Auboeuf, E Raspe et al., “The organization, promoter analysis, and expression of the human PPAR? gene,” Journal of Biological Chemistry, vol. 272, no. 30, pp. 18779–18789, 1997. View at Publisher · View at Google Scholar
  19. L Fajas, J-C Fruchart, and J Auwerx, “PPARγ3 mRNA: a distinct PPARγ mRNA subtype transcribed from an independent promoter,” FEBS Letters, vol. 438, no. 1-2, pp. 55–60, 1998. View at Publisher · View at Google Scholar
  20. H Sundvold and S Lien, “Identification of a novel peroxisome proliferator-activated receptor (PPAR) γ promoter in man and transactivation by the nuclear receptor RORα1,” Biochemical and Biophysical Research Communications, vol. 287, no. 2, pp. 383–390, 2001. View at Publisher · View at Google Scholar
  21. P Tontonoz, E Hu, R A Graves, A I Budavari, and B M Spiegelman, “mPPARγ2: tissue-specific regulator of an adipocyte enhancer,” Genes & Development, vol. 8, no. 10, pp. 1224–1234, 1994. View at Google Scholar
  22. K Al-Shali, H Cao, N Knoers, A R Hermus, C J Tack, and R A Hegele, “A single-base mutation in the peroxisome proliferator-activated receptor γ4 promoter associated with altered in vitro expression and partial lipodystrophy,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 11, pp. 5655–5660, 2004. View at Publisher · View at Google Scholar
  23. H-W Deng, F-H Xu, Q-Y Huang et al., “A whole-genome linkage scan suggests several genomic regions potentially containing quantitative trait loci for osteoporosis,” Journal of Clinical Endocrinology and Metabolism, vol. 87, no. 11, pp. 5151–5159, 2002. View at Publisher · View at Google Scholar
  24. Y H Lee, Y H Rho, S J Choi, J D Ji, and G G Song, “Meta-analysis of genome-wide linkage studies for bone mineral density,” Journal of Human Genetics, vol. 51, no. 5, pp. 480–486, 2006. View at Publisher · View at Google Scholar
  25. C Knouff and J Auwerx, “Peroxisome proliferator-activated receptor-γ calls for activation in moderation: lessons from genetics and pharmacology,” Endocrine Reviews, vol. 25, no. 6, pp. 899–918, 2004. View at Publisher · View at Google Scholar
  26. S Ogawa, T Urano, T Hosoi et al., “Association of bone mineral density with a polymorphism of the peroxisome proliferator-activated receptor ? gene: PPAR? expression in osteoblasts,” Biochemical and Biophysical Research Communications, vol. 260, no. 1, pp. 122–126, 1999. View at Publisher · View at Google Scholar
  27. E-J Rhee, K-W Oh, W-Y Lee et al., “The effects of C161?T polymorphisms in exon 6 of peroxisome proliferator-activated receptor-? gene on bone mineral metabolism and serum osteoprotegerin levels in healthy middle-aged women,” American Journal of Obstetrics and Gynecology, vol. 192, no. 4, pp. 1087–1093, 2005. View at Publisher · View at Google Scholar
  28. Y Hsu, Y Zhang, X Xu et al., “Genetic variation in Alox15, Bmp2, Pparg ? and Igf1 gene is associated with BMD,” Journal of Bone and Mineral Research, vol. 19, p. S386, 2004. View at Publisher · View at Google Scholar
  29. D P Kiel, S Ferrari, L A Cupples et al., “Polymorphisms in the PPAR? gene influence bone density in humans,” Journal of Bone and Mineral Research, vol. 20, p. S234, 2005. View at Google Scholar
  30. A Meirhaeghe, L Fajas, N Helbecque et al., “A genetic polymorphism of the peroxisome proliferator-activated receptor ? gene influences plasma leptin levels in obese humans,” Human Molecular Genetics, vol. 7, no. 3, pp. 435–440, 1998. View at Publisher · View at Google Scholar
  31. E J Rhee, K W Oh, W Y Lee et al., “Effects of two common polymorphisms of peroxisome proliferator-activated receptor-? gene on metabolic syndrome,” Archives of Medical Research, vol. 37, no. 1, pp. 86–94, 2006. View at Publisher · View at Google Scholar
  32. V Tavares, R D Hirata, A C Rodrigues et al., “Effect of the peroxisome proliferator-activated receptor-? C161T polymorphism on lipid profile in Brazilian patients with Type 2 diabetes mellitus,” Journal of Endocrinological Investigation, vol. 28, no. 2, pp. 129–136, 2005. View at Google Scholar
  33. P C Ng and S Henikoff, “Accounting for human polymorphisms predicted to affect protein function,” Genome Research, vol. 12, no. 3, pp. 436–446, 2002. View at Publisher · View at Google Scholar
  34. V Ramensky, P Bork, and S Sunyaev, “Human non-synonymous SNPs: server and survey,” Nucleic Acids Research, vol. 30, no. 17, pp. 3894–3900, 2002. View at Publisher · View at Google Scholar
  35. J M Zmuda, F Modugno, J L Weissfeld et al., “Peroxisome proliferator-activated receptor-? polymorphism, body mass and prostate cancer risk: evidence for gene-environment interaction,” Oncology, vol. 70, no. 3, pp. 185–189, 2006. View at Publisher · View at Google Scholar
  36. T Ostergard, J Ek, Y Hamid et al., “Influence of the PPAR-?2 Pro12Ala and ACE I/D polymorphisms on insulin sensitivity and training effects in healthy offspring of type 2 diabetic subjects,” Hormone and Metabolic Research, vol. 37, no. 2, pp. 99–105, 2005. View at Publisher · View at Google Scholar
  37. F Mousavinasab, T Tahtinen, J Jokelainen et al., “Effect of the Pro12Ala polymorphism of the PPAR?2 gene on serum adiponectin changes,” Endocrine, vol. 27, no. 3, pp. 307–309, 2005. View at Publisher · View at Google Scholar
  38. Y Barak, M C Nelson, E S Ong et al., “PPAR? is required for placental, cardiac, and adipose tissue development,” Molecular Cell, vol. 4, no. 4, pp. 585–595, 1999. View at Publisher · View at Google Scholar
  39. T Akune, S Ohba, S Kamekura et al., “PPAR? insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors,” The Journal of Clinical Investigation, vol. 113, no. 6, pp. 846–855, 2004. View at Publisher · View at Google Scholar
  40. J Rieusset, J Seydoux, S I Anghel et al., “Altered growth in male peroxisome proliferator-activated receptor ? (PPAR?) heterozygous mice: involvement of PPAR? in a negative feedback regulation of growth hormone action,” Molecular Endocrinology, vol. 18, no. 10, pp. 2363–2377, 2004. View at Publisher · View at Google Scholar
  41. M Matsushita, T Tsuboyama, R Kasai et al., “Age-related changes in bone mass in the senescence-accelerated mouse (SAM): SAM-R/3 and SAM-P/6 as new murine models for senile osteoporosis,” American Journal of Pathology, vol. 125, no. 2, pp. 276–283, 1986. View at Google Scholar
  42. R L Jilka, R S Weinstein, K Takahashi, A M Parfitt, and S C Manolagas, “Linkage of decreased bone mass with impaired osteoblastogenesis in a murine model of accelerated senescence,” Journal of Clinical Investigation, vol. 97, no. 7, pp. 1732–1740, 1996. View at Google Scholar
  43. M J Silva, M D Brodt, and S L Ettner, “Long bones from the senescence accelerated mouse SAMP6 have increased size but reduced whole-bone strength and resistance to fracture,” Journal of Bone and Mineral Research, vol. 17, no. 9, pp. 1597–1603, 2002. View at Publisher · View at Google Scholar
  44. O Kajkenova, B Lecka-Czernik, I Gubrij et al., “Increased adipogenesis and myelopoiesis in the bone marrow of SAMP6, a murine model of defective osteoblastogenesis and low turnover osteopenia,” Journal of Bone and Mineral Research, vol. 12, no. 11, pp. 1772–1779, 1997. View at Publisher · View at Google Scholar
  45. R F Klein, R J Turner, L D Skinner et al., “Mapping quantitative trait loci that influence femoral cross-sectional area in mice,” Journal of Bone and Mineral Research, vol. 17, no. 10, pp. 1752–1760, 2002. View at Publisher · View at Google Scholar
  46. T A Drake, E Schadt, K Hannani et al., “Genetic loci determining bone density in mice with diet-induced atherosclerosis,” Physiological Genomics, vol. 5, no. 4, pp. 205–215, 2001. View at Google Scholar
  47. W G Beamer, K L Shultz, L R Donahue et al., “Quantitative trait loci for femoral and lumbar vertebral bone mineral density in C57BL/6J and C3H/HeJ inbred strains of mice,” Journal of Bone and Mineral Research, vol. 16, no. 7, pp. 1195–1206, 2001. View at Publisher · View at Google Scholar
  48. M L Bouxsein, C Rosen, C H Turner et al., “Generation of a new congenic mouse strain to test the relationships among serum insulin-like growth factor I, bone mineral density, and skeletal morphology in vivo,” Journal of Bone and Mineral Research, vol. 17, no. 4, pp. 570–579, 2002. View at Publisher · View at Google Scholar
  49. C Rosen, C Ackert-Bicknell, M L Adamo et al., “Congenic mice with low serum IGF-I have increased body fat, reduced bone mineral density, and an altered osteoblast differentiation program,” Bone, vol. 35, no. 5, pp. 1046–1058, 2004. View at Publisher · View at Google Scholar
  50. C Ackert-Bicknell, C Marin-Bivens, J Denegre et al., “Metabolic and skeletal consequences of a high fat/diabetogenic diet on bone acquisition in a congenic mouse strain with altered osteoblast differentiation,” Journal of Bone and Mineral Research, vol. 20, p. S10, 2005. View at Google Scholar
  51. R F Klein, J Allard, Z Avnur et al., “Regulation of bone mass in mice by the lipoxygenase gene Alox15,” Science, vol. 303, no. 5655, pp. 229–232, 2004. View at Publisher · View at Google Scholar
  52. S Ichikawa, D L Koller, M L Johnson et al., “Human ALOX12, but not ALOX15, is associated with BMD in white men and women,” Journal of Bone and Mineral Research, vol. 21, no. 4, pp. 556–564, 2006. View at Publisher · View at Google Scholar
  53. N Kubota, Y Terauchi, H Miki et al., “PPAR ? mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance,” Molecular Cell, vol. 4, no. 4, pp. 597–609, 1999. View at Publisher · View at Google Scholar
  54. B Lecka-Czernik, E J Moerman, D F Grant, J M Lehmann, S C Manolagas, and R L Jilka, “Divergent effects of selective peroxisome proliferator-activated receptor-γ2 ligands on adipocyte versus osteoblast differentiation,” Endocrinology, vol. 143, no. 6, pp. 2376–2384, 2002. View at Publisher · View at Google Scholar
  55. S S Deeb, L Fajas, M Nemoto et al., “A Pro12Ala substitution in PPAR?2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity,” Nature Genetics, vol. 20, no. 3, pp. 284–287, 1998. View at Publisher · View at Google Scholar
  56. M Stumvoll and H Haring, “The peroxisome proliferator-activated receptor-γ2 Pro12Ala polymorphism,” Diabetes, vol. 51, no. 8, pp. 2341–2347, 2002. View at Publisher · View at Google Scholar
  57. I Barroso, M Gurnell, V EF Crowley et al., “Dominant negative mutations in human PPAR? associated with severe insulin resistance, diabetes mellitus and hypertension,” Nature, vol. 402, pp. 880–883, 1999. View at Publisher · View at Google Scholar
  58. D Evans, J De Heer, C Hagemann et al., “Association between the P12A and c1431t polymorphisms in the peroxisome proliferator activated receptor ? (PPAR?) gene and type 2 diabetes,” Experimental and Clinical Endocrinology and Diabetes, vol. 109, no. 3, pp. 151–154, 2001. View at Publisher · View at Google Scholar
  59. S Moffett, E Feingold, M Barmada et al., “The C161?T polymorphism in peroxisome proliferator-activated receptor gamma, but not P12A, is associated with insulin resistance in Hispanic and non-Hispanic white women: evidence for another functional variant in peroxisome proliferator-activated receptor?,” Metabolism, vol. 54, no. 11, pp. 1552–1556, 2005. View at Publisher · View at Google Scholar
  60. K M Thrailkill, C K Jr Lumpkin, R C Bunn, S F Kemp, and J L Fowlkes, “Is insulin an anabolic agent in bone? dissecting the diabetic bone for clues,” American Journal of Physiology - Endocrinology and Metabolism, vol. 289, no. 5, pp. E735–E745, 2005. View at Publisher · View at Google Scholar
  61. S Botolin, M-C Faugere, H Malluche, M Orth, R Meyer, and L R McCabe, “Increased bone adiposity and peroxisomal proliferator-activated receptor-γ2 expression in type I diabetic mice,” Endocrinology, vol. 146, no. 8, pp. 3622–3631, 2005. View at Publisher · View at Google Scholar
  62. P Ducy, M Amling, S Takeda et al., “Leptin inhibits bone formation through a hypothalamic relay: a central control of bone mass,” Cell, vol. 100, no. 2, pp. 197–207, 2000. View at Publisher · View at Google Scholar
  63. S Takeda, F Elefteriou, R Levasseur et al., “Leptin regulates bone formation via the sympathetic nervous system,” Cell, vol. 111, no. 3, pp. 305–317, 2002. View at Publisher · View at Google Scholar
  64. T Yamauchi, J Kamon, H Waki et al., “The mechanisms by which both heterozygous peroxisome proliferator-activated receptor ? (PPAR?) deficiency and PPAR? agonist improve insulin resistance,” Journal of Biological Chemistry, vol. 276, no. 44, pp. 41245–41254, 2001. View at Publisher · View at Google Scholar